Phase 1Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
- Sponsor
- Stemline Therapeutics, Inc. (Industry)
- Enrolment
- 240 planned
- Conditions
- Advanced Breast Cancer
- Interventions
- MEN2312; Elacestrant
- Ages
- adults, older adults
- Registry
- NCT06638307, CTIS2024-514661-19-00
Full record on ClinicalTrials.gov
From the registry
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Primary outcomes
- Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
- Recommended Phase 2 Dose (RP2D) of MEN2312
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered